SGS Increases Capacity for Human Challenge Studies
In collaboration with University Hospital Antwerp, SGS is building a new unit with a total capacity of 110 beds. This also includes a separate quarantine unit with 45 beds for CHIM studies. The move to the new unit is planned in mid-2021.
Annick Van Riel, Director Clinical Pharmacology Unit, SGS, said, "Challenge studies will continue to play a key role in the development of medicines and vaccines against infectious diseases in the future. These studies can be a crucial time saving in the clinical development of anti-viral drugs, among other things, by demonstrating efficiency and safety in a controlled environment in a fast and safe manner. That's why we've also decided to invest further in expanding our quarantine capacity in our new CPU. This will allow us to carry out more efficient and faster studies with large numbers of study participants."
Read the full release, here.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
